Tags

Type your tag names separated by a space and hit enter

Sacral Neuromodulation in a Patient with Wolff-Parkinson-White Syndrome: A Case Report.
Res Rep Urol. 2020; 12:193-197.RR

Abstract

Sacral neuromodulation has gained widespread use for bladder overactivity, frequency, urgency, fecal incontinence, and nonobstructive urinary retention; hence, implantations of this device in patients with comorbid cardiac conduction diseases have increased. Theoretically, there are some concerns regarding the use of sacral neuromodulation implants in patients with Wolf-Parkinson-White syndrome and cardiac conduction diseases because of the risk of interference with electrical impulses. This study aimed to describe the safety of using sacral neuromodulation to treat nonobstructive urinary retention in patients with a cardiac conduction disease. We report a case in which sacral neuromodulation was performed to treat nonobstructive urinary retention in a 25-year-old woman with Wolf-Parkinson-White syndrome who was receiving antiarrhythmic medication. The patient underwent magnetic resonance imaging of the spine and urodynamic studies after presenting with urinary symptoms at a urology clinic. She was then diagnosed with nonobstructive urinary retention. She underwent two-staged InterStim therapy, which involved implanting a permanent tined lead through the S3 foramen in the first stage and an implantable pulse generator in the second stage. The patient responded well to the therapy, and the frequency of clean intermittent catheterization was reduced from 6 times a day to once daily with only 250 mL drained per day. The cardiology team recommended intraoperative cardiac monitoring and postoperative electrocardiogram monitoring. No interference was observed between the implantable pulse generator and the cardiac rhythm on electrocardiography. She experienced no exacerbation of her cardiac symptoms. Sacral neuromodulation in a patient with Wolf-Parkinson-White syndrome appears to have been safe. Further, prospective and randomized studies with larger study samples are required to investigate the safety of these implants in WPW patients.

Authors+Show Affiliations

Department of Urology, College of Medicine, Majmaah University, Al-Majmaah, Saudi Arabia.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

32607315

Citation

Almutairi, Sulaiman. "Sacral Neuromodulation in a Patient With Wolff-Parkinson-White Syndrome: a Case Report." Research and Reports in Urology, vol. 12, 2020, pp. 193-197.
Almutairi S. Sacral Neuromodulation in a Patient with Wolff-Parkinson-White Syndrome: A Case Report. Res Rep Urol. 2020;12:193-197.
Almutairi, S. (2020). Sacral Neuromodulation in a Patient with Wolff-Parkinson-White Syndrome: A Case Report. Research and Reports in Urology, 12, 193-197. https://doi.org/10.2147/RRU.S258403
Almutairi S. Sacral Neuromodulation in a Patient With Wolff-Parkinson-White Syndrome: a Case Report. Res Rep Urol. 2020;12:193-197. PubMed PMID: 32607315.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sacral Neuromodulation in a Patient with Wolff-Parkinson-White Syndrome: A Case Report. A1 - Almutairi,Sulaiman, Y1 - 2020/06/17/ PY - 2020/04/15/received PY - 2020/06/08/accepted PY - 2020/7/2/entrez PY - 2020/7/2/pubmed PY - 2020/7/2/medline KW - Wolff-Parkinson-White syndrome KW - cardiac arrhythmia KW - idiopathic urinary retention KW - nonobstructive urinary retention KW - sacral neuromodulation SP - 193 EP - 197 JF - Research and reports in urology JO - Res Rep Urol VL - 12 N2 - Sacral neuromodulation has gained widespread use for bladder overactivity, frequency, urgency, fecal incontinence, and nonobstructive urinary retention; hence, implantations of this device in patients with comorbid cardiac conduction diseases have increased. Theoretically, there are some concerns regarding the use of sacral neuromodulation implants in patients with Wolf-Parkinson-White syndrome and cardiac conduction diseases because of the risk of interference with electrical impulses. This study aimed to describe the safety of using sacral neuromodulation to treat nonobstructive urinary retention in patients with a cardiac conduction disease. We report a case in which sacral neuromodulation was performed to treat nonobstructive urinary retention in a 25-year-old woman with Wolf-Parkinson-White syndrome who was receiving antiarrhythmic medication. The patient underwent magnetic resonance imaging of the spine and urodynamic studies after presenting with urinary symptoms at a urology clinic. She was then diagnosed with nonobstructive urinary retention. She underwent two-staged InterStim therapy, which involved implanting a permanent tined lead through the S3 foramen in the first stage and an implantable pulse generator in the second stage. The patient responded well to the therapy, and the frequency of clean intermittent catheterization was reduced from 6 times a day to once daily with only 250 mL drained per day. The cardiology team recommended intraoperative cardiac monitoring and postoperative electrocardiogram monitoring. No interference was observed between the implantable pulse generator and the cardiac rhythm on electrocardiography. She experienced no exacerbation of her cardiac symptoms. Sacral neuromodulation in a patient with Wolf-Parkinson-White syndrome appears to have been safe. Further, prospective and randomized studies with larger study samples are required to investigate the safety of these implants in WPW patients. SN - 2253-2447 UR - https://www.unboundmedicine.com/medline/citation/32607315/Sacral_Neuromodulation_in_a_Patient_with_Wolff-Parkinson-White_Syndrome:_A_Case_Report L2 - https://dx.doi.org/10.2147/RRU.S258403 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.